Use of Methazolamide to Lower Intraocular Pressure

Phase 4

Active, not recruiting

• Conditions: Glaucoma, Open-Angle
• Interventions: Drug: Methazolamide 50 MG; Drug: Methazolamide 25 MG

• Registration Number: NCT05498103
• Lead Sponsor: University of Colorado, Denver

Brief Summary

The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-08-09
• Study First Submitted QC: 2022-08-09
• Study First Posted: 2022-08-11
• Study Start: 2023-02-17
• Primary Completion: 2023-09-14
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-05
• Last Update Posted: 2024-02-06
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Males and females between 50 and 90 years old
• Current diagnosis of open angle glaucoma (OAG) in both eyes
• Ability to read and write in English

Read More

Exclusion Criteria

• Glaucoma other than OAG
• Severe or end-stage glaucoma (cup to disc ratio >0.8 or Mean Deviation on Visual Field worse than -12)
• Pregnant or breast-feeding women

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Methazolamide 50 mg	Methazolamide 50 MG	Once a day \[q.d\] in the morning for 1 week, Twice a day \[b.i.d.\] in the morning and evening for 1 week
Methazolamide 25 mg	Methazolamide 25 MG	Once a day \[q.d\] in the morning for 1 week, Twice a day \[b.i.d.\] in the morning and evening for 1 week

Primary Outcome Measures

Name	Time	Method
Percent IOP change at each follow-up Visit	Day 1 (Pre-dosing, then 4- and 8- hours post dosing), Day 7 (Pre-dosing, then 4- and 8- hours post dosing), Day 14 (Pre-dosing, then 4- and 8- hours post dosing)	IOP measure is measured using Goldmann Tonometry. IOP is measured in mmHg with a normal range from 12 mmHg to 22 mmHg.

Trial Locations

Locations (1)

Sue Anschutz-Rodgers Eye Center; 🇺🇸 Aurora, Colorado, United States